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Abstract: The critical role of the Hippo pathway has been recently investigated in various cancers,
but little is known about its role in glioblastoma (GBM). In order to evaluate the clinical relevance
of the Hippo pathway in GBM, we generated a core gene expression signature from four different
previously-established silence of Hippo pathway (SOH) signatures. Based on a newly generated
core SOH signature, a SOH and active Hippo pathway (AH) was predicted in GBM samples from
The Cancer Genome Atlas (TCGA) and validated in a separate cohort. A comparative analysis was
performed on multi-panel genomic datasets from TCGA and the possible association of SOH with
immune activity and epithelial mesenchymal transition was also evaluated. The SOH signature
was associated with poor prognosis in GBM in both cohorts. Expression levels of CTGF and CYR61,
the most reliable and well-known downstream targets of YAP1, were markedly increased in the SOH
subgroup of GBM patients. SOH signature was strongly associated with a high immune signature
score and mesenchymal features. Genes differentially expressed between SOH and AH groups
revealed many markers for inhibitory immune checkpoints and M2-polarized macrophages were
upregulated in the SOH subgroup, suggesting that SOH may induce the resistance of cancer cells to
host immune response in GBM. In summary, SOH is significantly associated with the poor prognosis
of GBM patients and is possibly mediated by pro-tumoral immunosuppression.
Keywords: glioblastoma; Hippo pathway; immune checkpoint; immune signature; macrophage;
M2 polarization
1. Introduction
Glioblastoma (GBM) is the most deadly cancer that develops in the central nervous system.
Since 2005, concomitant and maintenance treatment with temozolomide and radiotherapy has been the
standard treatment for patients with newly diagnosed GBM [1]. Most chemotherapeutic and targeted
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agents have failed to demonstrate superiority to this regimen, mainly because of tumor heterogeneity
and the blood–brain barrier [2].
The Hippo pathway is known to play a critical role in the regulation of tissue homeostasis, organ size
control, and stem cell renewal [3,4]. Moreover, an increasing number of reports have suggested that
the Hippo pathway contributes to cancer development and progression [3,5]. The kinase complex,
including STK3/4 (), SAV1, and LATS1/2, is the core functional component of the pathway, inhibiting the
oncogenic transcription activators YAP1 and TAZ (also known as WWTR1) through phosphorylation.
When YAP1 becomes unphosphrorylated, it enters a nucleus and activates various transcriptional
factors such as TEAD and SMAD, increasing gene expression involved in cell proliferation and
survival [6]. CYR61, CTGF and ANKRD1 are the most well-known downstream targets of YAP1 [6,7].
Despite numerous observations that the Hippo pathway is involved in various cancers [8], its role
in the development and progression of GBM has not been properly addressed, and the clinical
significance of the inactivation of the Hippo pathway has not been fully evaluated. Although the
inactivation of the Hippo pathway is generally associated with mutations in the Hippo pathway
components and the copy number amplification of YAP1, these are extremely rare in GBM (cBioPortal,
http://www.cbioportal.org/).
In our previous studies [9–11], we established gene expression signatures reflecting SOH in
stomach, liver, ovarian, and colorectal cancers and demonstrated that SOH signatures were associated
with poor prognosis in these four cancers. In the current study, by integrating four different SOH
signatures from different cancers, we identified a core SOH gene expression signature that was common
to all four cancer types and applied this core SOH signature to GBM tumors to assess the clinical
relevance of the Hippo pathway in GBM.
2. Materials and Methods
2.1. General Analytic Methods
To generate the core silence of Hippo pathway (SOH) signature, we used four SOH gene expression
signatures from our previous studies in which the role of the Hippo pathway was investigated in
four different cancers: colorectal, liver, ovarian, and stomach cancers [9–11]. Gene expression data for
colorectal, liver, ovarian, stomach cancers, and glioblastoma (GBM) from The Cancer Genome Atlas
(TCGA) project were obtained from a data portal site (https://tcga-data.nci.nih.gov). For validation,
expression data from another GBM dataset (GSE16011) were used (http://www.ncbi.nlm.nih.gov/geo).
Molecular characteristics of GBM tumors were retrieved from previous TCGA publications [12].
BRB-ArrayTools (http://linus.nci.nih.gov/BRB-ArrayTools.html) was used to analyze gene expression
data [13]. A heatmap was generated using Cluster and TreeView [14]. Other statistical analyses were
performed in the R language (http://www.r-project.org). We used the Bayesian covariate compound
predictor (BCCP) algorithm, which was described previously [15]. Survival analysis was performed
using the Kaplan–Meier method to compare groups. p values less than 0.05 were considered statistically
significant unless otherwise indicated.
2.2. Generation of a Core SOH Signature and Validation in GBM Datasets
A three-step approach was applied to generate the core SOH signature (Figure 1).
First, previously established SOH gene expression signatures from four cancer types were applied
to corresponding RNA-seq data from TCGA using the Bayesian covariate compound predictor (BCCP)
algorithm, as described in previous studies [16–19]. Tumor sample data from TCGA comprised 262
stomach tumors, 193 liver tumors, 266 ovarian tumors, and 286 colorectal tumors. Gene expression data
from the original signatures and TCGA were re-normalized by standardization before the prediction
model was applied. Tumors were then stratified into SOH or active Hippo pathway (AH) subgroups
according to corresponding SOH signatures. Second, genes differentially expressed between the SOH
and AH subgroups in each TCGA dataset were selected using the Student t-test with a cutoff of
Cells 2020, 9, 1761 3 of 16
p < 0.001 and at least a two-fold difference. This yielded 5585 genes for stomach cancer, 5988 genes for
liver cancer, 4127 genes for ovarian cancer, and 5859 genes for colorectal cancer. We then selected the































Figure 1. Schematic overview of the workflow for generation of the core silence of Hippo (SOH) gene
expression signature. Step 1: original SOH gene expression signatures from each cancer type were
applied to corresponding gene expression data from The Cancer Genome Atlas (TCGA) using the
Bayesian covariate compound predictor (BCCP) algorithm. Tumors in TCGA were stratified into SOH
or AH (active Hippo pathway) subgroups according to the corresponding SOH signature from each
cancer type. Step 2: differentially expressed genes between the SOH and AH subgroups in each cancer
type were identified by t-test (p < 0.001). Step 3: genes common to all four cancers were selected for the
core SOH signature (689 genes).
The core SOH signature generated from the four cancer types was used as a training set for further
analysis to assess the clinical relevance of the SOH signature in GBM. Briefly, gene expression data in this
training set were combined to form a classifier according to the BCCP algorithm. The robustness of the
classifier was estimated using a misclassification rate determined during leave-one-out cross-validation
in the training set. Then, the new BCCP classifier (689 genes in 1007 samples) estimated the likelihood
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that individual samples from GBM expression data have either the SOH or AH signature, according to
a Bayesian probability with a 0.5 cutoff. After stratification of tumors, the prognostic significance was
estimated using Kaplan–Meier analysis. The same prediction was performed for 172 samples from
TCGA including 154 primary and 13 recurrent GBMs and five samples of normal brain tissue.
2.3. Genomic Analysis of TCGA Cohort Data
Among 154 primary GBM samples with gene expression data (Illumina HiSeq 2000 RNA
Sequencing platform) retrieved from TCGA, copy number variation data were available in 148 samples
and somatic mutation data were available in 147 samples. GISTIC 2.0 copy number variation data were
used to generate a heatmap and graph showing the difference between the SOH and AH subgroups [20].
A previous TCGA study identified 71 significantly mutated genes in GBM, selected with a mutation
frequency above background with a q-value of <0.1 [12]. After excluding five genes in which no
mutation was found in any of the 154 samples, we compared the number of mutations per sample
between the two subgroups using the chi-square test.
2.4. Proteomics of TCGA Cohort Data
Reverse phase protein array (RPPA) data of TCGA samples were obtained from the TCGA RPPA
core at The University of Texas MD Anderson Cancer Center (Houston, TX, USA). Among the 154
primary GBM samples used in our study, RPPA data were available in 72 samples. The differences
in protein expression levels between the two subgroups were evaluated using the Student t-test and
p < 0.01 was considered statistically significant.
2.5. Comparison of mRNA Expression Levels and Pathway Analysis
The mRNA expression levels of Hippo pathway-related genes and Hippo target genes YAP1
and TAZ were compared between the SOH and AH subgroups in two cohorts: TCGA and GSE16011.
The expression level of CTGF, CYR61, and ANKRD1, the most reliable and well-known downstream
targets of YAP1 were also compared between two subgroups [7]. Markers for macrophages and their
polarized subtypes were selected on the basis of findings from previous studies, and differential
gene expression of these markers between the SOH and AH subgroups was investigated [21,22].
For comparative analysis of differential expression of inhibitory immune checkpoints between the SOH
and AH subgroups in TCGA and GSE16011, we retrieved the list of inhibitory immune checkpoint
molecules from a previous study [23].
For pathway analysis, differentially expressed genes were selected by comparing mRNA expression
levels of SOH and AH in TCGA samples using the Student t-test (p < 0.001) and at least a two-fold
difference. Data were analyzed using QIAGEN’s Ingenuity Pathway Analysis (IPA) (QIAGEN,
Redwood City, CA, USA; www.qiagen.com/ingenuity).
2.6. Immunohistochemistry on GBM Tissue
We retrieved the glioma dataset from The Human Protein Atlas (https://www.proteinatlas.org/)
and compared immunohistochemical (IHC) stains for YAP1 and PD-1 in 7 matched GBM samples.
Three GBM samples with positive IHC stain for nuclear YAP1 were considered as SOH and compared
with other 4 AH GBM samples. The correlation between YAP1 and PD-1 were evaluated by χ2 test.
2.7. Immune Signature Score (ISS) and Leukocyte Subset Analysis
The algorithm to generate the ISS was described in our previous study [24]. Briefly, a previously
identified 105-gene immune signature was used to generate ISS in GBM samples in the GSE16011
and TCGA datasets. Patients were stratified into high-ISS or low-ISS groups with an ISS cutoff of 0.5.
To assess the activity of immune cells in GBM tissues, we carried out a meta-analysis with CIBERSORT
(https://cibersort.stanford.edu), which can estimate the proportion of immune cells in a tumor mass
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from mRNA expression data [25]. Analyses were performed with 100 permutations using default
statistical parameters.
2.8. Transforming Growth Factor Beta (TGF-β) Signature
The TGF-β signature was obtained from a previous study in which GBM tumorspheres were
treated with galunisertib (LY2157299), a well-known TGF-β receptor 1 kinase inhibitor (GSE23935) [26].
A total of 284 differentially expressed genes was selected (p < 0.001) and used to construct a classifier.
One hundred fifty-four GBM samples were later dichotomized into active TGF-β and inactive TGF-β
subgroups, with a 0.5 cutoff. Associations between the TGF-β signature and the core SOH signature
and previously established molecular subtypes were evaluated.
2.9. Epithelial–Mesenchymal Transition Signature
In order to classify 154 GMB samples into high and low epithelial–mesenchymal transition
(EMT)-associated groups, 64-gene list was obtained from previous study on SNAI2-induced EMT [27].
Briefly, the average expression level of these 64 genes, which is referred as EMT metagene score in our
study, was calculated in each sample of TCGA cohort. According to EMT metagene score, the samples
were aligned and its association with Hippo signature and previously established molecular subtypes
was evaluated.
3. Results
3.1. Clinical Significance of Inactivation of the Hippo Pathway in GBM
Previous studies showed that the activity of the Hippo pathway is best reflected in transcriptome,
as final effectors of the Hippo pathway are transcription factors such as YAP1 and TAZ [9–11]. For a better
understanding of the underlying biology related to inactivation of the Hippo pathway (or activation of
YAP1/TAZ) in cancer, we generated a core SOH gene expression signature by re-analyzing previously
established SOH signatures from stomach, liver, ovarian, and colorectal cancers, as described in
Materials and Methods (Figure 1). Interestingly, the vast majority of genes in the core SOH signature
were upregulated in the SOH subgroups across the four cancer types, suggesting that many of these
genes might be direct targets of YAP1/TAZ, which are best known as transcription activators. In fact,
the best known direct downstream targets of YAP1/TAZ, such as CTGF and CYR61 [7], were significantly
upregulated in the SOH subgroups.
Once we had a core SOH signature that accurately reflected the inactivation of the Hippo pathway
regardless of cancer type or organ site, we applied the signature to gene expression data from GBM
tumor samples in TCGA to stratify patients, using the previously established BCCP algorithm [16–19].
When dichotomized into SOH (53 patients) and AH (101 patients) subgroups (Figure 2A), patients in
the SOH subgroup had significantly shorter overall survival (p = 0.029; Figure 2B), suggesting that
activation of YAP1/TAZ is associated with poor prognosis in GBM.
Among the four previously recognized molecular subtypes (classical, mesenchymal, neural,
and proneural) [28], the mesenchymal subtype was associated with the SOH signature (p < 0.001 by
chi-square test, Figure 2A), suggesting that the acquisition of the mesenchymal phenotype might be
mediated by activation of YAP1/TAZ in GBM. Consistent with the association of the SOH signature with
poor prognosis, tumors in the SOH subgroup lacked the glioma CpG island methylation phenotype
that is typically associated with improved prognosis in GBM (Figure 2A) [29]. The incidence of
promoter methylation of methylguanine methyl transferase was not associated with either the SOH or
AH signature (Figure 2A). The core SOH signature-based prediction of 172 TCGA samples including
primary, recurrent GBM and normal brain, demonstrated recurrent samples were more common in the
SOH, whereas all normal brain tissue samples were classified as AH (Figure S1).
We further tested the association of the SOH signature with poor prognosis in an independent GBM
cohort, GSE16011. When 96 GBM patients were stratified into the SOH or AH subgroups (Figure 2C),
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Kaplan–Meier plots showed a significant association between the gene signature and overall survival
(p = 0.027, Figure 2D), strongly supporting the robustness of the signature and association of YAP1/TAZ
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Figure 2. Association of the silence of Hippo pathway (SOH) signature with poor prognosis in patients
with glioblastoma (GBM). (A) Heat map of gene expression patterns of GBM tumor samples from The
Cancer Genome Atlas (TCGA; n = 154), which were stratified according to core SOH signature by the
Bayesian covariate compound predictor (BCCP) classifier. Of 154 patient samples, 53 were placed in
the SOH subgroup and 101 were placed in the active Hippo (AH) subgroup. The data are presented
in matrix format in which rows represent individual genes and columns represent individual tumor
samples. Samples are arranged according to SOH probability from BCCP. Mesenchymal subtypes
were more common in the SOH subgroup, whereas proneural subtypes were more abundant in the
AH subgroup (p < 0.001). The incidence of glioma CpG island methylation phenotype (G-CIMP) and
promoter methylation of methylguanine methyl transferase (MGMT) are indicated. (B) Kaplan–Meier
plots of overall survival (OS) of patients in the SOH and AH subgroups in TCGA. (C) Heatmap of gene
expression data from GBM tumors in GSE16011 (44 SOH and 52 AH). (D) Kaplan–Meier plots of OS of
patients in the SOH and AH subgroups in GSE16011. p values were obtained using the log-rank test.
3.2. Genomic and Proteomic Characteristics Associated with the SOH Signature
In TCGA, somatic mutation analysis revealed that overall somatic mutation burden was not
significantly different between the SOH and AH subgroups or among the four previously recognized
molecular subtypes (Figure S2). Copy number variations were not significantly different between
the SOH and AH subgroups either (Figure S3). In the analysis on proteomic characteristics of GBM
by using RPPA data, we identified 48 protein features associated with the SOH signature (p < 0.01;
Figure S4).
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3.3. Molecular Characteristics Associated with the SOH Signature
We next identified genes whose expression was significantly different between the SOH and AH
subgroups (p < 0.001) in TCGA, yielding 904 genes (Table S1). When the gene expression levels of
upstream members of Hippo pathway such as LATS1, LATS2, SAV1 were compared between SOH and
AH subgroups, only MST2 and LATS2 were upregulated in SOH subgroup, which revealed that they
may be not the leading cause of YAP1 activation (Figure 3). Expression of YAP1 was not significantly
different between the two subgroups, which may be attributed to the fact that regulation of YAP1
function largely depends on its phosphorylation state and on the site of the phosphorylation. On the
contrary, expression of TAZ was significantly higher in the SOH subgroup, suggesting that TAZ may
play more of a role in GBM (Figure 3). Likewise, among four TEAD family members, expression of
TEAD3 and TEAD4 was significantly higher in the SOH subgroup, further supporting isoform-specific
activation of the YAP1/TAZ-TEAD pathway in GBM. Consistent with the increased expression of TAZ
and TEAD3/4, expression of CTGF and CYR61, the best known downstream targets of YAP1/TAZ [7],
were significantly higher in the SOH subgroup than in the AH subgroup. This observation is further
supported by our finding that expression of CTGF and CYR61 was significantly higher in the SOH








































































































P < 0.001 P < 0.001 P < 0.001
P = 0.103 P = 0.965 p=0.0003 P < 0.001
P = 0.987
P = 0.445 P = 0.010 P = 0.480 P = 0.855 P < 0.001
P < 0.001
Figure 3. Differential gene expression levels of Hippo–YAP pathway-related genes in The Cancer
Genome Atlas. The expression level of TAZ was elevated in the silence of Hippo (SOH) subgroup,
although the gene expression level of YAP1 did not differ between the SOH and active Hippo (AH)
subgroups. The SOH subgroup showed higher levels of TEAD3 and TEAD4 gene expression. Above all,
the expression level of CTGF and CYR61, the most reliable and well-known downstream targets of YAP1,
were markedly increased in the SOH subgroup. Differential gene expression of upstream members
of Hippo pathway showed MST2 and LATS2 are upregulated in SOH subgroup revealing that these
genes are not responsible for Hippo pathway inactivation.
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To assess the underlying biology associated with the SOH subgroup, we carried out gene network
analysis using IPA with 904 differentially expressed genes. Interestingly, many signaling pathways
related to immune response, such as TREM1 signaling, dendritic cell maturation, iCOS-iCOSL signaling
in T helper cells, and CD28 signaling in T helper cells, were significantly enriched in the SOH subgroup
(Figure 4).
Role of NFAT in Regulation of the Immune Response
Cd28 Signaling in T Helper Cells
Communication between Innate and Adaptive Immune Cells
iCOS-iCOSL Signaling in T Helper Cells
Leukocyte Extravasation Signaling
Acute Phase Response Signaling
Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses
Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis
IL-10 Signaling
Phagosome formation
T Helper Cell Differentiation
Complement System
Altered T Cell and B Cell Signaling in Rheumatoid Arthritis




Agranulocyte Adhesion and Diapedesis
Hepatic Fibrosis / Hepatic Stellate Cell Activation
Granulocyte Adhesion and Diapedesis
P-values (−log10)
0 10 20 30 40
positive z-score
z-score = 0
no activity pattern available
Figure 4. Pathway analysis based on 904 genes differentially expressed between the silence of
Hippo (SOH) and active Hippo subgroups in The Cancer Genome Atlas. The top 20 canonical
pathways are shown. Only pathways with significant positive z-score are marked with color. Various
immune-associated pathways are significantly enriched in the SOH subgroup.
Consistent with these findings, cytokines such as TNF, TGFB1, INFG, IL-1B, and IL-4 were
predicted as potential upstream regulators in gene network analysis (Table S2). More interestingly,
many inhibitory immune checkpoint genes, such as CTLA4, PD-1, and PD-L2, were upregulated in
the SOH subgroup, suggesting that YAP1/TAZ may induce resistance of cancer cells to host immune
response in GBM (Figure 5). Because transcriptionally active YAP1 is typically localized in nuclei [6],
we examined the IHC staining of YAP1 and PD-1 in GBM tissues. In good agreement with observation
from genomic data, nuclear YAP1 staining is highly correlated with PD-1 staining (Figure S6).
3.4. Immunologic Features Associated with Activation of YAP1/TAZ in GBM
Because gene network analysis strongly suggested that the SOH signature may be associated
with immune-related pathways, we further analyzed genomic data to determine whether YAP1/TAZ
plays a role in regulation of the host immune response to cancer cells. We previously developed ISS by
adopting 105 immune signature genes selected by comparing expression data between responders
and non-responders to immunotherapy [24]. We applied the ISS algorithm to gene expression data
from 154 GBM tissues and dichotomized the samples into high- and low-ISS subgroups (cutoff of 0.5).
Consistent with gene network analysis, the SOH subgroup was associated with high ISS (p < 0.001,
chi-square test; Figure 6A), further supporting the potential role of YAP1/TAZ in immune response to
GBM. The mesenchymal subtype had the highest ISS and the proneural subtype had the lowest ISS
(Figure 6B), suggesting that SOH is associated with the mesenchymal subtype. This association was
further validated in an independent cohort of GBM patients (Figure S7A).
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Figure 5. Gene expression levels of inhibitory checkpoint molecules in the silence of Hippo (SOH)
and active Hippo (AH) subgroups in The Cancer Genome Atlas. Most inhibitory checkpoints were
markedly upregulated in the SOH subgroup.
To assess immune cell components that are most likely accountable for the high immune activity
in the SOH subgroup, we applied meta-analysis to gene expression data from GBM tissue using
CIBERSORT. This analysis revealed that the M2 macrophage was the most abundant immune cell
component in GBM (Figure 6A), and the SOH subgroup showed much higher proportions of M2
macrophages (42.8% compared with 34.6% for AH; p < 0.001). We next compared the expression levels
of macrophage surface makers, including general markers for macrophages and specific markers for
M2 polarized macrophages. Expression of M2 polarized macrophage markers was significantly higher
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in the SOH subgroup than in the AH subgroup (Figure S8). Differential expression of M2 markers
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Figure 6. Immune signature of glioblastoma (GBM) samples from The Cancer Genome Atlas (TCGA).
The immune signature score (ISS) was predicted for each of the 154 samples on the basis of a
105-gene immune signature generated from a comparative analysis of responders and nonresponders
to immunotherapy. (A) In a heatmap showing the core immune signature of the 154 samples, high ISS
was more common in the silence of Hippo (SOH) subgroup (p < 0.001). Leukocyte subset analysis
(CIBERSORT) showed that the proportion of M2 macrophages in GBM tumor tissue was much higher
in the SOH subgroup than in the active Hippo (AH) subgroup. BCCP, Bayesian covariate compound
predictor. (B) ISS was apparently highest in the mesenchymal subtype, followed by the neural subtype,
and it was lowest in the proneural subtype.
3.5. TGF-β Signature and Inactivation of the Hippo Pathway
Because TGF-β is the most well-known immunosuppressive molecule particularly associated
with the mesenchymal phenotype [30], we investigated whether the TGF-β pathway is associated
with immune activity as well as activation of YAP1/TAZ in GBM. When a 284-gene TGF-β classifier
was applied to TCGA data, the SOH subgroup had significantly higher TGF-β activity than the AH
subgroup (p < 0.001, chi-square test; Figure S10A). GBM samples with the active TGF-β signature also
apparently showed much higher ISSs (p < 0.001, Figure S10B). The gene expression level of TGF-β
was positively correlated with all M2 markers, including MRC1, CD163, TREM2, IL-10, and ARG1,
and CLEC7A was the marker most well correlated with TGF-β (Figure S10C).
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3.6. Epithelial–Mesenchymal Transition and Inactivation of the Hippo Pathway
When TCGA GBM samples were predicted based on 64 genes of EMT signature, GBM samples
with SOH signature demonstrated higher EMT metagene scores (Figure S11). Between BCCP value of
SOH and EMT metagene score, there was a strong positive correlation (r = 0.830).
4. Discussion
The inactivation of the Hippo pathway in cancers is mediated by various genetic and epigenetic
events. The Hippo pathway is a very complex regulatory network as reflected by many upstream
regulators in the pathway. However, the vast majority of pathway activity is largely mediated by
two transcription regulators YAP1 and TAZ. Many previous studies showed that their activity is best
reflected in the transcriptome as they are strong transcription regulators [3,6]. We used transcription
signatures adopted from multiple datasets reflecting the inactivation of STK3/4 and SAV1 (key negative
regulators of YAP1 and TAZ) to identify tumors with inactivated Hippo pathways regardless of their
genetic or epigenetic alterations in the Hippo pathway. In fact, their key transcription targets such as
CTGF, CYR61, and ANKRD1 are significantly more expressed in SOH, strongly supporting that the
core SOH signature is a good indicator of Hippo pathway activity.
When we stratified GBM patients based on the core SOH signature, the activation of YAP1/TAZ was
associated with poor prognosis in GBM. The association was tested and validated in two independent
cohorts of patients. A further in-depth analysis of genomic data revealed that activation of YAP1/TAZ
might be associated with increased host immune activity. Many inhibitory immune checkpoint
genes were upregulated in the SOH subgroup (Figure 5), which possibly results in pro-tumoral T-cell
exhaustion in GBM [31,32]. More interestingly, high immune activity in the SOH subgroup was
associated with an increased fraction of M2 polarized macrophages that can suppress immune cell
activity. Thus, our analysis may provide novel biological insight into the poor prognosis associated
with the SOH signature in GBM.
The analysis of TCGA data showed that inactivation of the Hippo pathway was more frequently
observed in the mesenchymal subtype, suggesting that the inactivation of the Hippo pathway may be
associated with EMT, consistent with previous observations [33]. In order to evaluate the association
of SOH with EMT, we adopted an EMT metagene scoring system from a previous study based on a
glioblastoma cell line model [27]. When the EMT metagene scores of each GBM TCGA sample were
measured based on the expression levels of 64 EMT-related genes, most of the 64 genes were upregulated
in a SOH subgroup (Figure S10). Additionally, we performed the same prediction for 13 samples of
recurrent GBM and five samples of normal brain tissue, together with the 154 samples of primary
GBM, from TCGA to evaluate the SOH signature in recurrent GBM. Considering that GBM acquires
mesenchymal features at recurrence regardless of the original subtype [28], it is not surprising that most
of the recurrent GBM samples we examined exhibited the SOH signature and all normal brain tissues
were skewed to the AH subgroup (Figure S1). In the RPPA analysis on the TCGA cohort, we identified
48 proteins associated with the SOH signature (Figure S4). Among them, we identified 48 protein
features associated with the SOH signature many proteins known to be associated with poor prognosis
in GBM, such as SERPINE1, FN1, CAV1, IGFBP2, HSPA1A, and SYK [34–38], were upregulated in
the SOH subgroup, strongly suggesting potential cross-talk between the Hippo pathway and other
signaling pathways associated with poor prognosis in GBM. Although the association of these proteins
with the Hippo pathway has not been investigated extensively, recent reports suggested that some of
these proteins are possibly controlled by the Hippo pathway [39,40]. More interestingly, the expression
and activation of EGFR was negatively correlated with inactivation of the Hippo pathway, suggesting
that the activation of YAP1 and TAZ might be mutually exclusive with activation of the EGFR pathway
in GBM. The 904 genes differentially expressed between the SOH and AH subgroups, as well as the
pathway analysis, strongly suggested that SOH is associated with the activation of many immune
molecules and pathways. Most notably, well-known macrophage-associated genes, including MARCO,
FPR2, MRC1, POSTN, CSF3, CD163, and TREM1, were among the most upregulated genes in the
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SOH subgroup. Our ISS system, which was designed to estimate the probability of response to
immune-based therapy, predicted that GBM samples with the SOH signature had high immune
activity. Although high immune activity is generally correlated with high mutational burden (increased
neo-antigen presentation) [41], no difference was found in mutational burden between the SOH and
AH subgroups, suggesting that GBM with the SOH signature gains high immunogenicity through
mutation-independent mechanisms.
Although tumors with an increased immune signature generally show better prognosis than
those with decreased immune signatures, we did not observe a survival benefit from high ISS in our
study. The in-depth analysis of genomic data suggested that the high ISS in the SOH subgroup may be
associated with the innate immune system, and more specifically, with macrophages. Macrophages are
among the most abundantly recruited immune cells in the tumor microenvironment. Two distinct
states of polarized activation for macrophages have been defined: the classically activated macrophage
phenotype (M1) with an antitumor effect and the alternatively-activated macrophage phenotype (M2)
with a pro-tumoral and immunosuppressive effect [42,43]. In most solid cancers, M2 macrophages
comprise the majority of tumor-associated macrophages [43], and the proportion of M2 macrophages is
higher in GBM than in any other major cancer [44]. We postulated that tumor-associated macrophages
may play pro-tumoral roles when the Hippo pathway is inactive, leading to poor prognosis despite
the high overall immune activity in the SOH subgroup. Indeed, mRNA expression of all M2-specific
markers was upregulated in the SOH subgroup in two independent GBM cohorts. Our observation
that inhibitory immune checkpoint genes showed increased expression in the SOH subgroup also
supports this hypothesis. Moreover, our hypothesis is in good agreement with previous observations
that increased tumor-infiltrating lymphocytes and macrophages are most common in the mesenchymal
subtype of GBM, for which survival is the worst among the four subtypes [45]. Recent reports showed
that targeting M2 macrophages in a GBM mouse model led to a remarkable survival benefit by
inhibiting CSF-1R, an M2-related marker [46], which also strongly supports our hypothesis.
TGF-β promotes pro-tumoral immunosuppression. As a pleiotropic cytokine, TGF-β maintains
immune homeostasis through the regulation of all cell types of the innate and adaptive immune
system [47]. In our pathway analysis, TGF-β was suggested as a key upstream regulator. In particular,
TGF-β is known to be a strong inducer of the M2 polarization of macrophages [48]. The critical
role of TGF-β in the epithelial–mesenchymal transition has also been demonstrated in many cancer
models, including GBM [30,49]. On the basis of this supporting evidence, we postulated that the
TGF-β signaling pathway may be associated with the inactivation of the Hippo pathway. The SOH
signature was strongly correlated with the active TGF-β signature, which was also associated with
high ISS and mesenchymal features. Our results suggest that TGF-β might be another potential target
that inhibits M2 polarized macrophages in GBM. Currently, there are several TGF-β inhibitors being
tested in clinical trials for several cancer types, including GBM, and the preliminary results have been
encouraging [50].
Our study has several limitations. Since our SOH signature is not derived from GBM tissues,
predicted YAP1 activity in GBM might be underestimated due to the lack of expression data
reflecting neuronal specific YAP1 activity. Therefore, SOH and its possible crosstalk with the cancer
microenvironment should be further investigated directly based on GBM cell lines and mouse models
as suggested by Okazaki et al. [51]. Secondly, because this is an association study, which is the main
limitation of our study, further investigation is needed to verify our hypothesis and to elucidate the
pro-tumoral mechanism of M2 macrophages. Furthermore, it is currently unknown if the activation
of M2 macrophages is mediated by YAP1/TAZ. Although some of the association from our analysis
of genomic data is functionally relevant as evidenced by good correlation between active YAP1 and
PD-1 staining of infiltrated cells in IHC staining of GBM tissues, more analysis and experimental
approaches will be needed for functional validation. Lastly, our signature may be more related to
YAP1/TAZ activity than the inactivation of the Hippo pathway, as some of upstream regulators such
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as MST2 and LATS are more expressed in SOH. YAP1 and TAZ might be activated independent of
upstream regulators.
In summary, GBM showing the SOH signature was associated with an increased ISS, suggesting
that these patients might be good potential candidates for immunotherapy. Many inhibitory immune
checkpoint genes are upregulated in the SOH subgroup, suggesting that YAP1/TAZ may induce the
resistance of cancer cells to host immune response in GBM. M2 polarized macrophages may be another
important component of pro-tumoral immunosuppression in GBM with a possible association with
SOH, and thus can be another possible target of immunotherapy. Targeting the Hippo pathway and
associated TGF-β pathway might be a useful approach to enhance the clinical benefit of immunotherapy
in GBM.
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